CSPC PHARMA (01093) announced the financial results of CSPC Innovation Pharmaceutical (300765.SZ) for the first three quarters. The group recorded revenue of RMB1.593 billion, a year-on-year increase of 7.71%. However, it reported a net loss attributable to shareholders of RMB24.05 million, with a basic loss per share of RMB0.0173.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.